United Therapeutics Corporation (UTHR)

From the record

United Therapeutics Corporation's filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

United Therapeutics Corporation's 10 filed years say what it did: revenue went from $1.6 billion in fiscal 2016 to $3.2 billion in fiscal 2025, up 8% a year; it rose in 7 of 9 years; the deepest fall was 16% from fiscal 2017 to fiscal 2019; net income was positive in 5 of 5 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, United Therapeutics Corporation's diluted share count shrank about 0.4% a year, and dividends and buybacks returned about 52% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 2897 sales (2883 under scheduled 10b5-1 plans) and 1 purchase of their own stock on the open market in the year to 2026-11-12, buying about $864 thousand (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, United Therapeutics Corporation earned about 19 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 36 cents per dollar of everything the company owns. Leverage: it owed about 10 cents per dollar of assets, and net share issuance: its share count shrank 1.2% over the year (the filed statements).

From the record

United Therapeutics Corporation's standing among 315 graded names in its industry family: revenue of $3.2 billion in fiscal 2025 ranks in the top 8% by size; a net margin of 41.9% ranks in the top 6%; revenue growth of 18% a year over the last 3 filed years ranks in the top 39% (its annual reports).

From the record

United Therapeutics Corporation's leadership, from its insiders' filings and its current reports: the chief executive on the record is Rothblatt, Martine A (Chairperson & CEO, as filed), filing under that title since 2024-06-03, 2.4 years (bottom 27% of its family); the 16 officers and directors filing in the last fifteen months have been on the record a median of 14.3 years (top 2%); 5 officer or director changes were reported on Form 8-K since 2023-11-13, against the 16 people in charge now (top 31%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

United Therapeutics Corporation's room to grow, from the newest filed statements (fiscal 2025): cash of $1.6 billion against no long-term debt tagged leaves 19.8% of its assets as net cash, bottom 39% of its family; cash from operations less capital spending is 32.7% of revenue (top 6%); a gross margin of 87.9% (top 20%); research spending of 17.3% of revenue (bottom 22%) (its annual report).

From the record

United Therapeutics Corporation's growth drivers, from the filed years to fiscal 2025: revenue grew 18% a year over the last three filed years against 8% over all 10, speeding up (top 19% of its family); the newest year grew 10.6% (top 46%); research spending grew 19.4% a year (top 25%); capital spending grew 55.3% a year (top 13%) (its annual reports). United Therapeutics Corporation reported 7 product lines in fiscal 2025: Tyvaso DPI at $1.3 billion (41%), Nebulized Tyvaso at $586 million (18%), Remodulin at $527 million (17%), and 4 more; 4 of 7 grew against the year before (its annual report).

From the record

United Therapeutics Corporation's newest year against its own record: revenue of $3.2 billion in fiscal 2025 came in 9.3% below the $3.5 billion its prior three years' pace pointed to (bottom 39% of its family); net income of $1.3 billion against a prior three-year average of $969 million (top 38%); a net margin of 41.9% against 40.5% before (bottom 38%) (its annual reports).